Clostridioides difficile Infections (Clostridium difficile Associated Disease) is an indication for drug development with over 80 pipeline drugs currently active. According to GlobalData, preregistered drugs for Clostridioides difficile Infections (Clostridium difficile Associated Disease) have a 100% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Clostridioides difficile Infections (Clostridium difficile Associated Disease) compared to historical benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Clostridioides difficile Infections (Clostridium difficile Associated Disease) overview
Clostridium difficile infections are caused by Clostridium difficile, often called C. difficile or “C. diff”, a bacterium that can cause symptoms ranging from diarrhea to life-threatening inflammation of the colon. Symptoms of C. diff infection include watery diarrhea with abdominal pain or tenderness, loss of appetite, fever, blood or pus in the stool, and weight loss. Risk factors are age, surgery of the gastrointestinal (GI) tract, a weakened immune system, kidney disease, use of proton-pump inhibitor medications, and use of chemotherapy drugs. This condition may be controlled by the use of medication such as antibiotics and may be prevented by lifestyle modification.
See Also:
For a complete picture of PTSR and LoA scores for drugs in Clostridioides difficile Infections (Clostridium difficile Associated Disease), buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
